Materials

Company Presentation

Corporate presentation

Download (1.67 MB)

Press releases

July 26 2021

Global experts on the Genomtec Scientific Advisory Board

The Company has appointed a Scientific Advisory Board consisting of global experts in healthcare systems management and technology. The Board’s mission is to support Genomtec in the further development of the Company’s innovative technology, its business and products clinical development. Current appointees to the Scientific Advisory Board include: Eric Garnier – with 35 years of experience in the medical industry, and Prof. Krishnendu Chakrabarty – winner of numerous scientific awards, and holder of 18 patents in the US market, specializing in the area of microfluidic techniques. It is predicted for the future to extend appointees to the Scientific Advisory Board for specialists in the field of diagnostics and treatment of infectious diseases.
June 24 2021

Genetic tests Genomtec SARS-CoV-2 Duo Kit (Cat. no.: GA00B) and Direct-RT-LAMP Kit (Cat. no.: GA00C) detect multiple virus lineages

As part of our standard product surveillance and assurance strategy, and also due to growing concerns on ability of IVD tests to recognize newly appearing SARS-CoV-2 variants, Genomtec conducted bioinformatic (in-silico) as well as the wet lab analysis of its products, Genomtec® SARS-CoV-2 EvaGreen® RT-LAMP CE-IVD Duo Kit (RT-LAMP Duo) and Genomtec® SARS-CoV-2 EvaGreen® Direct-RT-LAMP CE-IVD Kit (Direct).
June 23 2021

Jarosław Oleszczuk changes his scope of involvement in Genomtec transiting from Management Board to Supervisory Board

The company announced in the draft resolution of the Extraordinary General Meeting of Shareholders convened on July 20 this year, with the intention to appoint Dr. Jarosław Oleszczuk to the Supervisory Board of Genomtec. At the time of publication of the draft resolution announcement by Genomtec Dr. Jarosław Oleszczuk resigned from his current position of a Member of the Management Board with an effect on June 23 this year. From August 1 this year the CBO role will be assigned to by Charudutt Shah – a newly appointed Member of the Genomtec’s Management Board.
May 31 2021

Genomtec strengthens the management board – Charudutt Shah joins the company

Genomtec SA announced that Charudutt Shah is joining the board. The newly appointed member of the Genomtec board is a senior executive with many years of international experience, incl. in the area of business development, marketing and sales management and strategic planning in the clinical genetic diagnosis sector. He will start work at Genomtec on August 1, 2021.
May 25 2021

Genomtec expands patient group in the additional comparative study of its COVID-19 test directly from saliva

The company will conduct additional comparative study of its test detecting SARS-CoV-2 directly from saliva sample utilizing the Direct-RT-LAMP technology against the reference RT-PCR method, executed via the agreement signed with the Cellgen Molecular Pathology Center (NZOZ Aurimed). The comparative study will be performed in the Cellgen’s laboratory. The acquired clinical data will enrich positive results obtained from currently running clinical validation research at the Central Clinical Hospital of the Ministry of Interior and Administration, which enabled market authorisation of the product in the European Union.
May 17 2021

Genomtec launches the world’s first genetic diagnostic test for the detection of SARS-CoV-2 directly from a saliva sample

Genomtec SA has registered and launched in the European Union market the Genomtec® SARS-Cov-2 EvaGreen® Direct-RT-LAMP CE-IVD Kit (RT-LAMP Direct Kit), which enables identification of SARS-CoV-2 infection from the patient’s saliva. The innovative test will provide patients with greater comfort due to lack of swabbing, e.g. from the nasopharynx. The possibility of testing using saliva will also reduce the risk of virus’ contraction by the personnel collecting the sample, additionally sampling does not require specialized skills.
May 10 2021

Genomtec receives the third patent based on the LAMP technique

The company has been granted a patent protection from the Patent Office of the Republic of Poland for a set of primers amplifying Borrelia burgdorferi’s nucleotide sequence , i.e. the bacteria causing Lyme disease. The patent developed by the Genomtec team covers the method of detecting Borrelia burgdorferi, the method of Lyme disease diagnosis, and a diagnostic kit for Lyme disease. It is the second patent granted by the Patent Office of the Republic of Poland and the third patent received by the Company. Currently, Genomtec has got pending twenty patent applications worldwide.
April 30 2021

DCM DOLMED S.A. is becoming the reference laboratory for products offered by Genomtec S.A.

The company signed an agreement with the Lower Silesian Medical Center DOLMED S.A. – the leader of multidisciplinary healthcare provision in Wroclaw and Lower Silesia. The cooperation’s aim is to commence offering Genomtec’s products and services for patients in DCM DOLMED’s genetic diagnostic laboratory utilizing RT-LAMP technique for SARS-CoV-2 testing using Genomtec® SARS-CoV-2 EvaGreen® RT -LAMP CE-IVD Duo-Kit (RT-LAMP Duo Kit). Due to the close cooperation of both entities DOLMED will become the reference laboratory for products offered by Genomtec S.A.
April 22 2021

Genomtec submits yet another patent application in the LAMP technology confirming implementation of its work plan dedicated to Genomtec ID

Genomtec SA filed yet another significant patent application to The Polish Patent Office, Republic of Poland. The patent application concerns the proprietary set of primers, the diagnostic method and the reaction mixture composition for genetic diagnosis of MRSA (methicillin-resistant staphylococcus aureus) in the LAMP technique. The assay is part of the systemic infections diagnostic panel planned for Genomtec ID – a mobile genetic testing platform dedicated for doctor’s office, ambulance, airport or pharmacy.